Search clinical trials for: hyd-sulfate AZD6244

Total 99 results

AstraZeneca

Terminated

Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

Inoperable Locally Advanced or Metastatic Biliary Tract Cancer

Japan
AstraZeneca

Active, not recruiting

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Melanoma | Kidney Cancer | Breast Cancer | Breast Neoplasms | Lung Cancer | Colon Cancer | Colonic Cancer | Colon Neoplasms

United States
The Christie NHS Foundation Trust
AstraZeneca; Cancer Research UK

Terminated

Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial (DREAMtherapy)

Rectal Cancer

United Kingdom
M.D. Anderson Cancer Center
AstraZeneca; MedImmune LLC

Withdrawn

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma | Advanced Lung Cancer | Recurrent Nonsmall Cell Lung Cancer
AstraZeneca

Completed

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

Healthy Volunteers Bioavailability Study

United Kingdom
AstraZeneca

Completed

A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244 (AZD6244Formula)

Healthy Volunteers

United States
National Cancer Institute (NCI)

Active, not recruiting

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Carcinoma, Non-Small-Cell Lung | Carcinoma, Small Cell Lung | Carcinoma, Thymic

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb; AstraZeneca

Terminated

Personalized Treatment Selection for Metastatic Breast Cancer

Breast Cancer

United States
AstraZeneca

Completed

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

Healthy Volunteers Bioequivalence or Bioavailability Study

United Kingdom
AstraZeneca

Completed

Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies

Melanoma | Malignant Melanoma

United Kingdom, Netherlands
National Cancer Institute (NCI)

Completed

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Selumetinib in Cancers With BRAF Mutations

Adult Solid Neoplasm

United States
The Christie NHS Foundation Trust
AstraZeneca; University of Manchester

Completed

MEK Inhibitor and Thoracic Radiotherapy Trial (MEKRT)

Non Small Cell Lung Cancer

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Solid Neoplasm

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm

United States
Dana-Farber Cancer Institute
National Comprehensive Cancer Network

Active, not recruiting

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Non-small Cell Lung Cancer

United States
Tanta University

Completed

Aminophylline Infusion on Pain Intensity After Ureterocopic Lithotripsy

Pain | Aminophylline | Ureterocopic Lithotripsy

Egypt
National Cancer Institute (NCI)
NRG Oncology

Completed

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
The Netherlands Cancer Institute
AstraZeneca; Boehringer Ingelheim

Unknown

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer (M14AFS)

Gastrointestinal Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms

Netherlands
AstraZeneca

Completed

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Non Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, Canada, Brazil, Hungary, Peru, Czechia, Bulgaria, Mexico
National Cancer Institute (NCI)

Completed

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Iris Melanoma | Stage IV Uveal Melanoma | Medium/Large Size Posterior Uveal Melanoma | Recurrent Uveal Melanoma | Ocular Melanoma With Extraocular Extension | Small Size Posterior Uveal Melanoma

United States, Canada
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Recurrent Extrahepatic Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Cancer | Liver and Intrahepatic Biliary Tract Cancer

United States
Russian Academy of Medical Sciences
Russian Society of Clinical Oncology

Unknown

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Triple Negative Breast Cancer
National Cancer Institute (NCI)
National Comprehensive Cancer Network

Completed

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States
National Cancer Institute (NCI)

Terminated

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma | Refractory Primary Central Nervous System Neoplasm | Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma and other conditions

United States, Puerto Rico
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Recruiting

Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
University of Birmingham
Pfizer; AstraZeneca; Mirati Therapeutics Inc.; Cancer Research UK; Experimental Cancer...

Active, not recruiting

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Adenocarcinoma | Carcinoma, Squamous Cell | Non-Small Cell Lung Cancer

United Kingdom
AstraZeneca

Active, not recruiting

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies

Cancer | Tumor

United States, Netherlands, United Kingdom
University Health Network, Toronto

Active, not recruiting

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

Gallbladder Carcinoma | Biliary Tract Carcinoma

Canada
University of Pennsylvania
University of Arizona; National Center for Advancing Translational Sciences... and other collaborators

Completed

FEnofibRate as a Metabolic INtervention for COVID-19 (FERMIN)

Covid19

United States
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Completed

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); GlaxoSmithKline; Merck Sharp & Dohme LLC; Nova...

Completed

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer

Colon Cancer | Colonic Neoplasms | Colonic Cancer | Cancer of the Colon | Colon Neoplasms

United States
Swiss Group for Clinical Cancer Research

Completed

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Breast Cancer

Switzerland, Belgium
National Cancer Institute (NCI)
University of Chicago; City of Hope Medical Center; University of Southern California and other collaborators

Completed

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Non Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

Adult Solid Neoplasm

United States
AstraZeneca

Completed

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

Solid Tumours

United States
Merck Sharp & Dohme LLC
AstraZeneca

Completed

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Locally Advanced or Metastatic Solid Tumors
M.D. Anderson Cancer Center
AstraZeneca

Active, not recruiting

Selumetinib and Olaparib in Solid Tumors

Malignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Thyroid and Other Endocrine Glands | Malignant Neoplasms of Digestive Organs | Malignant Neoplasms of Male Genital Organs

United States
AstraZeneca

Active, not recruiting

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)

Muscle Invasive Bladder Cancer

Spain, United States, Canada, France, United Kingdom
National Cancer Institute (NCI)

Terminated

A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

Non-Metastatic Adenocarcinoma of the Rectum

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; Genzyme, a Sanofi Company

Completed

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Thyroid Cancer

United States
AstraZeneca

Completed

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Bulgaria, Romania
AstraZeneca

Completed

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

Metastatic Colorectal Cancer

Brazil
AstraZeneca

Completed

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

Melanoma

United States, Australia, Brazil, United Kingdom, Argentina, Austria, Canada, Denmark, France, Switzerland
AstraZeneca

Completed

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Pancreatic Cancer

United States, Bulgaria, Hungary, Romania, Australia
National Cancer Institute (NCI)
NRG Oncology

Completed

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

Primary Peritoneal Carcinoma | Low Grade Ovarian Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Primary Peritoneal Low Grade Serous Adenocarcinoma | Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor

United States

Search clinical trials for: hyd-sulfate AZD6244

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations